
Oscar Reig
Servicio de Oncología Médica OncólogoGrupo de investigación
- Genómica traslacional y terapias dirigidas en tumores sólidos Accredited researcher (R3A)
Publicaciones destacadas
-
Prognostic impact of micromegakaryocytes in primary myelodysplastic syndromes
Autores:Referencia: Leukemia & Lymphoma 2022. -
Pathogenesis of penile squamous cell carcinoma: Molecular update and systematic review
Autores:Referencia: International Journal Of Molecular Sciences 2022. -
Clinicopathological and Molecular Prognostic Classifier for Intermediate/High-Risk Clear Cell Renal Cell Carcinoma
Autores:Referencia: Cancers 2021. -
A renal cell carcinoma tumorgraft platform to advance precision medicine
Autores:Referencia: Cell Reports 2021. -
Glutamine and cholesterol plasma levels and clinical outcomes of patients with metastatic castration-resistant prostate cancer treated with taxanes
Autores:Referencia: Cancers 2021. -
Outcomes of systemic targeted therapy in recurrent RCC Renal Cell Carcinoma treated with adjuvant sunitinib
Autores:Referencia: Bju International 2021. -
Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer
Autores:Referencia: Frontiers In Oncology 2020. -
DUTRENEO Trial: A randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature.
Autores:Referencia: Journal Of Clinical Oncology 2020. -
Outcomes of systemic therapy in relapsed renal cell carcinoma (RCC) treated with adjuvant sunitinib (AS)
Autores:Referencia: Journal Of Clinical Oncology 2020. -
Response to immunotherapy, platinum-based chemotherapy or their combination in metastatic urothelial carcinoma (MUC) with or without FGFR-3 alterations: Single cohort experience
Autores:Referencia: Journal Of Clinical Oncology 2020.
Proyectos destacados
-
Perfil molecular asociado al beneficio a la inmunoterapia en pacientes con cáncer de próstata hormonosensible: Estudios traslacionales asociados al ensayo clínico PROSTRATEGY
Investigador/a principal: Oscar Reig TorrasDuración: 01/01/2022 - 31/12/2024 -
Remodelación del microambiente tumoral mediante la modulación del secretoma para mejorar la respuesta a la inmunoterapia en el carcinoma renal de células claras
Duración: 01/01/2022 - 31/12/2024 -
Molecular and functional characterization of BAP1/PBRM1 double-mutant clear cell renal cell carcinoma.
Investigador/a principal: Oscar Reig TorrasDuración: 01/04/2019 - 01/04/2020 -
Celular plasticity and immune profile and its relationship with therapeutic response in patients with metastatic prostate cancer.
Investigador/a principal: Jose Garcia CorbachoCódigo: PI18/00714Duración: 01/01/2019 - 01/01/2021 -
Exploratory study of the role of TMPRSS2-ERG expression and associated transcriptional profile in metastatic castration-sensitive prostate cancer patients treated with hormonal therapy and taxanes
Investigador/a principal: Oscar Reig TorrasDuración: 01/01/2018